Duke Center for Atrial Fibrillation, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Duke Center for Atrial Fibrillation, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.
JACC Heart Fail. 2019 Jun;7(6):447-456. doi: 10.1016/j.jchf.2019.03.005.
Heart failure and atrial fibrillation are 2 common cardiovascular disorders that frequently complicate one another and exert a significant detrimental effect on cardiovascular health and well-being. Both heart failure and atrial fibrillation continue to increase in prevalence as the risk factors underlying each condition become more common. This review encompasses what is currently known about the epidemiology and pathophysiology of these comorbidities along with incorporation of landmark trials that have contributed to current guidelines. The focus is on clinically relevant considerations, including the contribution of inflammation in the pathophysiology of atrial fibrillation and heart failure. We explore the emerging role of catheter ablation relative to medical therapy in the management of heart failure with reduced ejection fraction, along with indications for biventricular pacing modalities in cardiac resynchronization therapy. We discuss current guideline-directed therapies and how practice models and national recommendations will likely change based on the most recent randomized controlled trials.
心力衰竭和心房颤动是两种常见的心血管疾病,它们经常相互复杂化,并对心血管健康和福祉产生重大不利影响。随着每种疾病的潜在风险因素变得更加普遍,心力衰竭和心房颤动的患病率继续增加。本综述涵盖了目前对这些合并症的流行病学和病理生理学的了解,以及对促成当前指南的里程碑式试验的了解。重点是临床相关的考虑因素,包括炎症在心房颤动和心力衰竭病理生理学中的作用。我们探讨了导管消融相对于心力衰竭射血分数降低患者的药物治疗的新兴作用,以及心脏再同步治疗中双心室起搏模式的适应证。我们讨论了当前指南指导的治疗方法,以及根据最近的随机对照试验,实践模式和国家建议可能会发生怎样的变化。